Research programme: gonadotropin releasing hormone antagonists - Paradigm Therapeutics

Drug Profile

Research programme: gonadotropin releasing hormone antagonists - Paradigm Therapeutics

Alternative Names: PTD 634

Latest Information Update: 13 Feb 2008

Price : $50

At a glance

  • Originator Paradigm Therapeutics
  • Developer Takeda Cambridge
  • Class Small molecules
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Prostate cancer

Most Recent Events

  • 08 Nov 2006 Preclinical data have been added to the pharmacokinetics, adverse events and Cancer pharmacodynamics sections
  • 08 Nov 2006 PTD 634 has been selected as a clinical development candidate for hormone-dependent prostate cancer
  • 10 Jan 2005 Amedis Pharmaceuticals has been acquired and merged into Paradigm Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top